10-Q: Orgenesis Inc. Reports Q3 2024 Results Amidst Nasdaq Delisting and Strategic Shifts

Orgenesis Inc. reported its Q3 2024 results, marked by a Nasdaq delisting, the reconsolidation of Octomera, and various strategic transactions.

Summary

• Orgenesis Inc. reported a net loss of $28.6 million for the nine months ended September 30, 2024, compared to a net loss of $58.3 million for the same period in 2023.
• Revenue increased to $734,000 for the nine months ended September 30, 2024, up from $365,000 in the same period of 2023.
• The company's operating loss was $21.6 million for the nine months ended September 30, 2024, compared to $46.9 million for the same period in 2023.
• The company's common stock was delisted from the Nasdaq Capital Market and began trading on the OTCQX on October 21, 2024.
• Orgenesis reconsolidated Octomera LLC into its accounts on January 29, 2024, after previously deconsolidating it on June 30, 2023.
• The company entered into debt exchange agreements, exchanging $16 million of debt for equity.
• The company entered into asset purchase agreements with Broaden Bioscience and Technology Corp. and Theracell Advanced Biotechnology S.A.
• The company entered into a strategic partnership agreement with Harley Street Healthcare Group (London) Plc Ltd.

Sentiment

Score: 3

Explanation: The document highlights significant financial challenges, including a going concern warning, Nasdaq delisting, and a material weakness in internal controls. While there are some positive developments like revenue growth and strategic partnerships, the overall sentiment is negative due to the company's financial instability and operational risks.

Positives

• Revenue increased by 101% for the nine months ended September 30, 2024, compared to the same period in 2023.
• The net loss decreased significantly from $58.3 million to $28.6 million year-over-year for the nine months ended September 30, 2024.
• The company successfully exchanged $16 million of debt for equity, improving its capital structure.
• The company entered into strategic partnerships and asset purchase agreements, expanding its technology and market reach.

Negatives

• The company's common stock was delisted from the Nasdaq Capital Market, which may make it more difficult to raise capital.
• The company has an accumulated deficit of $204.4 million and negative operating cash flows of $14.9 million for the nine months ended September 30, 2024.
• The company has a material weakness in its internal control over financial reporting related to revenue recognition and credit losses.
• The company has a working capital deficit of $33.5 million as of September 30, 2024.

Risks

• The company has substantial doubt about its ability to continue as a going concern.
• The company may be unsuccessful in raising the capital necessary to address its going concern issues.
• The delisting from Nasdaq could adversely affect the company's ability to raise additional capital.
• The company's operations in Israel may be affected by economic, political, and military conditions.
• The company's internal control over financial reporting has a material weakness.

Future Outlook

The company plans to raise additional capital to continue operations, repay outstanding loans, increase revenues, and reduce or delay expenditures. There is no assurance that the company will be able to raise additional capital on acceptable terms.

Management Comments

• Management has assessed the company's financial condition and concluded that there is substantial doubt about its ability to continue as a going concern.
• Management is planning to raise additional capital to continue operations and repay outstanding loans.

Industry Context

The company operates in the Cell and Gene Therapy (CGT) sector, which is characterized by high development costs and complex logistics. Orgenesis is focused on developing autologous therapies that can be manufactured near the patient, which is a growing trend in the industry to reduce costs and improve accessibility.

Comparison to Industry Standards

• The company's revenue growth of 101% year-over-year is significant, but the absolute revenue remains low compared to established biotech companies.
• The company's net loss, while reduced, is still substantial, indicating ongoing challenges in achieving profitability.
• The delisting from Nasdaq is a significant setback, as it reduces access to capital and investor confidence, which is a common challenge for smaller biotech companies.
• The company's focus on point-of-care manufacturing aligns with industry trends towards decentralized production, but the company's financial instability poses a risk to its ability to execute this strategy.
• The company's strategic partnerships and asset acquisitions are positive steps, but their impact on the company's financial performance remains to be seen.

Legal Proceedings

• The company is involved in several legal proceedings, including a complaint in the Tel Aviv District Court regarding royalty payments, a claim in the Tel Aviv District Court regarding finders fees, a complaint in the Supreme Court of the State of New York regarding a convertible loan agreement, and a claim in the Tel Aviv District Court regarding unsecured convertible note agreements.
• The company reached a settlement agreement regarding unpaid rentals with a lessor of leased premises.

Stakeholder Impact

• Shareholders face significant risks due to the company's financial instability and delisting from Nasdaq.
• Employees may be affected by potential cost-cutting measures and the company's financial challenges.
• Customers may be impacted by the company's ability to deliver products and services due to its financial instability.
• Creditors face increased risk of non-payment due to the company's financial challenges.

Next Steps

• The company plans to raise additional capital to continue its operations.
• The company will explore additional avenues to increase revenues and reduce or delay expenditures.
• The company will continue to implement its strategic partnerships and asset purchase agreements.

Key Dates

Keywords

Orgenesis, Cell and Gene Therapies, CGT, POCare, Nasdaq delisting, Octomera, Debt exchange, Strategic partnership, Asset purchase, Financial results